Home › Interstitial Lung Diseases › New York
Pag-aaral pangklinika para sa Interstitial Lung Diseases sa New York
19 pag-aaral para sa Interstitial Lung Diseases ang naghahanap ng mga kalahok sa mga site sa New York.
Mga Lungsod sa New York
Opisyal na teksto ng pag-aaral (English)
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Weill Cornell Medicine-New York-60569, New York
Nagre-recruitPhase 3
Edad 40 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07201922A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Icahn School of Medicine at Mount Sinai, New York
Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06968845Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Weill Medical College of Cornell University, New York
Nagre-recruitObservasyonal na pag-aaral
Edad 21 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01915511FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Weill Cornell Medicine-New York-60569, New York
- New York Presbyterian Hospital -Columbia University, New York
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07540988Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Buffalo, Buffalo
- Weill Cornell University Medical College, New York
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06911632Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA005, New York
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT07179380RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
Nagre-recruitPhase 2/3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 16, 2026 · NCT06328777A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- NYU Langone Health, New York
- University of Rochester Medical Center, Rochester
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT07285655A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), East White Plains
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07323732A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, New York
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Northwell Health, New Hyde Park
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital - Weill Cornell Medicine, New York
- at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- Weill Cornell Medicine, New York
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06855329The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
- University of Rochester Medical Center, Rochester
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT07561034Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Northwell Health, New Hyde Park
- Weill Cornell Medicine, New York-Presbyterian Hospital, New York
- Stony Brook Advanced Specialty Care, Stony Brook
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT05943535Cough Capture as a Portal Into the Lung
- Albert Einstein College of Medicine, The Bronx
Nagre-recruitObservasyonal na pag-aaral
Edad 21 pataas · Lahat ng kasarian · Na-update Ene 13, 2026 · NCT05854563Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2025 · NCT05892614Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.